Actively Recruiting
Evaluating Safety and Clinical Activity of GSK5926371 in Adults with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Led by GlaxoSmithKline · Updated on 2026-10-30
49
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug GSK5926371 for treating adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma B-NHL, a type of blood cancer that has returned or not responded to previous treatments. This Phase 12 open-label study aims primarily to assess the safety and tolerability of GSK5926371. The study also seeks to measure the drugs clinical efficacy and how it behaves in the body pharmacokinetics. Participants will receive GSK5926371 at different dose levels to evaluate its effects. The study is designed as a sequential interventional trial without masking or placebo comparison. The treatment phase will last up to approximately 169 weeks, during which participants are monitored closely for dose limiting toxicities, adverse events, and clinical response. During the trial, participants will undergo regular assessments including laboratory tests, vital signs, electrocardiograms, and measures of drug concentration in the blood. Researchers will track safety outcomes for up to 28 days for dose limiting toxicities and for about 169 weeks for other adverse events and response rates. The total participation time may extend over several years, reflecting the long-term monitoring planned to evaluate the treatments clinical activity and safety.
CONDITIONS
Brief Title
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here